Cell & Tissue Bank

The PRF Cell & Tissue Bank provides researchers worldwide with genetic and biological material from Progeria patients and their families as well as lonafarnib, fueling scientific progress on Progeria and other aging-related diseases.

200+

Cell lines available

200+

Laboratories served

29

Countries reached

WHY THE BANK MATTERS

Because Hutchinson-Gilford Progeria Syndrome (Progeria) is extremely rare, a central repository with a sufficient number of samples is essential to facilitate global research. The PRF Cell & Tissue Bank fills that need, growing from just a few cell lines at its founding in 2002 to over 200 today. The bank was instrumental in discovering the gene mutation responsible for Progeria and in testing multiple treatments in preclinical studies.

Goals

Ensure sufficient availability of cells for approved research projects
Incentivize new research projects globally
Support the study of the biochemical basis of Progeria
Discover relationships between Progeria and generalized aging
Advance discoveries leading to new treatments for children with Progeria
Contribute to finding a cure for Progeria

AVAILABLE MATERIALS & ORDERING

To order, complete an Application and Material Transfer Agreement (MTA) and submit to Wendy Norris at [email protected].

[View available cell lines]

[View sequencing histograms]

[Cell & Tissue Bank recipients]

Material	Cost	Application / MTA	Protocols
Fibroblast or lymphoblast cell line	$150	Application and Agreement for Non-government Institutions Material Transfer Agreement for Non-government Institutions**	Culturing lymphoblasts Subculturing and freezing fibroblasts
Immortalized fibroblast cell line	$150	Application and Agreement for Non-government Institutions Material Transfer Agreement for Non-government Institutions**	Immortalized cell culture protocols
Induced pluripotent stem cell (iSPC) line*	$500	Application and Agreement for Non-government Institutions Material Transfer Agreement for Non-government Institutions**	iPSC Technical and Ordering Information iPSC cell culture protocols
Lonafarnib for preclinical research	No cost (recipient pays shipping)	Application and Agreement Material Transfer Agreement for Non-government Institutions**	Technical Notes: Solubility Administration

*iPSC lines ship from Ottawa Hospital Research Institute; the researcher will be invoiced directly by OHRI
**PRF has a policy of no changes to our MTA.

CONTACT

Wendy Norris
Research Assistant
[email protected]
401-274-1122 x48063

IRB APPROVAL

The PRF Cell & Tissue Bank is IRB-approved by the Rhode Island Hospital Committee on the Protection of Human Subjects — Federal Wide Assurance FWA00001230, study CMTT#0146-09.

PUBLICATIONS

For all publications resulting from the use of biological samples from the PRF Cell and Tissue Bank, we ask researchers to please use the following information within the materials and methods section (not simply the acknowledgments). This wording may vary slightly, depending on which materials were supplied for the research:

“Cells and Cell Culture; Human primary dermal fibroblast cell lines were obtained from The Progeria Research Foundation (PRF) Cell and Tissue Bank. The HGPS cell lines were XXX, XXX, XXX; the control lines were XXX, XXX, XXX.”

For publications listed by cell line inclusion, Click here.

For publications listed by biological sample inclusion, Click here.

For publications listed by Zokinvy (lonafarnib) inclusion, Click here.

SPECIAL THANKS

PRF has partnered with the Ottawa Hospital Research Institute (OHRI) for storage and distribution of iPSC lines. Many thanks to Dr. William Stanford and Dr. Wing Chang for establishing the iPSC branch of this bank.

Thank you to the many foundations that have supported the PRF Cell & Tissue Bank with generous grants, and to Sharon Terry (Genetic Alliance), Dr. David Kiszkiss (Brown University Research Foundation), and Claire Driscoll (National Human Genome Research Institute) for their help in establishing the bank.